Editorial Board About Us

Benjamin M Brucker

All articles from this author are listed below.

Volume 18, Number 3 Meeting Reviews

Highlights From the 2016 American Urological Association Annual Meeting

Stacy Loeb J Curtis Nickel Michael A Gorin Michael K Brawer Benjamin M Brucker Dean G Assimos Ellen Shapiro Alan W Partin Michael B Chancellor

More than 2000 posters, abstracts, and videos were presented at the 2016 American Urological Association (AUA) Annual Meeting, held in San Diego, CA, from May 6 to 10, 2016. The editors of Reviews in Urology have culled an enormous volume of information from this premier source and present the findings that are most relevant to the practicing urologist. [Rev Urol. 2016;18(3):159-173 doi:10.3909/riu0717] © 2016 MedReviews®, LLC

Prostate cancer Active surveillance Disorders of sexual development Nephrolithiasis Overactive bladder Microbiome OnabotulinumtoxinA Hemorrhagic cystitis Inflammation Four kallikrein assay Genomic prostate score

Volume 19, Number 1 NYU Case of the Month

Urinary Incontinence in a Noncatheterizing Woman With Multiple Sclerosis

Benjamin M Brucker

[Rev Urol. 2017;19(1):49-51 doi: 10.3909/riu0751] © 2017 MedReviews®, LLC

Volume 20, Number 2 Review Articles

Botulinum Toxin Use in Neurourology

Systematic Review

Gregory Vurture Benoit Peyronnet Xavier Gamé Victor W Nitti Benjamin M Brucker

The use of botulinum toxin A (BTX-A) has revolutionized the treatment of neurogenic lower urinary tract dysfunction (NLUTD) over the past three decades. Initially, it was used as a sphincteric injection for detrusor sphincter dyssynergia but now is used mostly as intradetrusor injection to treat neurogenic detrusor overactivity (NDO). Its use is supported by high-level-of-evidence studies and it has become the gold-standard treatment for patients with NDO refractory to anticholinergics. Several novelties have emerged in the use of BTX-A in neurourology over the past few years. Although onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA) remains the only BTX-A for which use is supported by large, multicenter, randomized, controlled trials (RCT), and is therefore the only one to be licensed in the United States and Europe, a second BTX-A, abobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Basking Ridge, NJ), is also supported by high-level-of-evidence studies. Other innovations in the use of BTX-A in neurourology during the past few years include the BTX switch (from abobotulinumtoxinA to onabotulinumtoxinA or the opposite) as a rescue option for primary or secondary failures of intradetrusor BTX-A injection and refinements in intradetrusor injection techniques (number of injection sites, injection into the trigone). There is also a growing interest in long-term failure of BTX-A for NDO and their management, and a possible new indication for urethral sphincter injections. [Rev Urol. 2018;20(2):84–93 doi: 10.3909/riu0792] © 2018 MedReviews®, LLC

Botulinum toxin Neurogenic detrusor overactivity Sphincter Injection

Volume 20, Number 4 NYU Case of the Month

Female Urethral Stricture

NYU Case of the Month, September 2018

Benjamin M Brucker

[Rev Urol. 2018;20(4):174–176 doi: 10.3909/riu0824A] © 2019 MedReviews®, LLC

Volume 20, Number 4 Case Review

Nocturia: Finding an Identity

Benjamin M Brucker

Nocturia is a condition that has a tremendous impact on a patient’s health and wellbeing. Getting up 2 or more times a night to urinate fragments sleep, preventing deep, restorative stages of the sleep cycle. With safer and more effective therapies, nocturia is a treatable condition that no longer should be overlooked. The simplicity of directly targeting the cause of nocturia, the overproduction of urine (ie, nocturnal polyuria) should be considered. Noctiva™ (desmopressin acetate) nasal spray (Avadel Pharmaceuticals plc, Chesterfield, MO), a novel FDA-approved microdose desmopressin nasal spray, can reduce nighttime urine production and potentially mitigate the potential harm of nocturia. [Rev Urol. 2018;20(4):170–173 doi: 10.3909/riu0822] © 2019 MedReviews®, LLC

Quality of life BPH Lower urinary tract symptoms (LUTS)Desmopressin acetate

Volume 21, Number 2 Review Articles

Nocturia in Patients With Multiple Sclerosis

Management Review

Carrie Lyn Sammarco Roger R Dmochowski W Stuart Reynolds Benoit Peyronnet Xavier Gamé Lauren B Krupp Gérard Amarenco Jean-Nicolas Cornu Lana Zhovtis Ryerson Jonathan E Howard Robert W Charlson Benjamin M Brucker

The prevalence of nocturia in patients with multiple sclerosis (MS) is high, ranging from 20.9% to 48.8% in this population. Its underlying pathophysiology is complex and different from the non-neurogenic population. In the MS population, the pathophysiology may involve neurogenic lower urinary tract dysfunction (NLUTD) such as detrusor overactivity (NDO), detrusor-sphincter dyssynergia, or detrusor underactivity resulting in reduced bladder capacity. Nocturnal polyuria is also a significant contributor to the pathogenesis of nocturia in MS patients and may be the result of specific mechanisms such as nocturnal hypertension through autonomic cardiovascular dysfunction or lack of diurnal variation of antidiuretic hormone production (ADH) due to demyelinating lesions of the spinal cord. Nocturia might be particularly burdensome in MS patients by contributing to fatigue, a common and highly debilitating symptom in this population. There is likely a complex and multidirectional relationship between nocturia, other sleep disorders, and fatigue in the MS population that has yet to be explored. The assessment of nocturia in MS should rely upon a thorough history and physical examination. Urinalysis should be done to rule out urinary tract infection, a frequency-volume chart might help elucidating the underlying mechanisms, and post-void residual volume may be of interest to screen for urinary retention that could be asymptomatic in MS patients. Other tests such as urodynamics or polysomnography are indicated in selected patients. The treatment should be tailored to the underlying cause. The first steps involve behavioral interventions and treatment of cofactors. When possible, the predominant mechanism should be addressed first. In case of predominant NDO, antimuscarinics and beta-3 agonists should be offered as a first-line treatment and intradetrusor injections of botulinum toxin as a second-line treatment. In cases of incomplete bladder emptying, clean-intermittent self-catheterization is often used as part of multiple other interventions. In cases of nocturnal polyuria, desmopressin may be offered, inclusive of use of newer formulations (desmopressin acetate nasal spray, desmopressin orally disintegrated tablet) in countries where they are approved. [Rev Urol. 2019;21(2/3):63–73] © 2019 MedReviews®, LLC

Nocturia Multiple sclerosis Fatigue Desmopressin Nocturnal polyuria voiding diary

Volume 21, Number 2 Review Articles

Primary Bladder Neck Obstruction

Disease State Review

Rachael D Sussman Benjamin M Brucker Alice Drain

Primary bladder neck obstruction (PBNO) is a functional obstruction caused by abnormal opening of the bladder neck during the voiding phase of micturition. PBNO may present with a variety of symptoms including voiding symptoms (slow urinary stream, intermittent stream, incomplete emptying), storage symptoms (frequency, urgency, urgency incontinence, nocturia), and/or pelvic pain and discomfort. The diagnosis of PBNO can be made with videourodynamic testing, which demonstrates elevated voiding pressures with low flow, and fluoroscopic imaging demonstrating obstruction at the level of the bladder neck. Treatment options include conservative management with watchful waiting, pharmacologic management, and surgical intervention. In this article, we review the etiology, presentation, diagnosis, and treatment of PBNO in men, women, and children. [Rev Urol. 2019;21(2/3):53–62] © 2019 MedReviews®, LLC

Lower urinary tract symptoms Bladder outlet obstruction Primary bladder neck obstruction

Volume 22, Number 4 NYU Case of the Month

Surgical Management of the “Large” Prostate: The Robotic Simple Prostatectomy

NYU Case of the Month, October 2020

Alice Drain Benjamin M Brucker

[Rev Urol. 2020;22(4):174–176] © 2021 MedReviews®, LLC